[British Medical Journal Publishing Group 25th EAHP Congress, 25thâ27th March 2020, Gothenburg, Sweden - ()] Section 2: Selection, Procurement and Distribution - 2SPD-006â Assessment of regorafenib, ramucirumab and cabozantinib as secondline therapy in hepatocarcinoma and alfa-fetoprotein value â¥400 ng/mL
Camean-Castillo, M, Fenix-Caballero, S, Salmeron-Navas, FJ, Dominguez-Cantero, M, Borrero-Rubio, JMDOI:
10.1136/ejhpharm-2020-eahpconf.25
File:
PDF, 59 KB